feb 11, 2019: 1:30 p.m. - 2:30 p.m.
As biomedical innovation has developed advanced therapeutic modalities and prospective cures for ailments that previously had no comparable courses of treatment, the challenge of crafting sustainable reimbursement models has inspired a variety of value-based agreements. Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy%u2019s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers%u2019 expectations for future models of reimbursing treatments based on outcomes versus delivery.
Moderator: Yasmeen Rahimi, Managing Director and Senior Research Analyst Biotechnology, ROTH Capital Partners